Compounds of the formula I ##STR00001## in which R.sup.1, R.sup.4, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

A TLR-independent adjuvant compound that corresponds in structure to Formula I, below, or its pharmaceutically acceptable salt is disclosed in

##STR00001##

which X, Y, Z, n, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and W are defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.

Compounds of general formula I that are capable of inhibiting bacterial pyruvate kinase and/or bacterial growth. The compounds may find use as antibacterial agents in therapeutic and/or non-therapeutic contexts.

Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing. Pharmaceutical composition containing antagonists. Methods employing antagonists and agonists for modulation of quorum sensing. Compounds are exemplified by those of formula:
A-[Z].sub.n-L1-[Y].sub.q-W-[V].sub.m-L2-HG,
where A is an acyclic aliphatic group, and HG is an optionally substituted phenyl group. Compounds include those where m and n are both 0, W is —NH—, Y is present and is —CO—CH.sub.2—CO—, and L1 and L2 independently are —[CH.sub.2].sub.p1— and —[CH.sub.2].sub.p2—, where p1 and p2, independently, are 0 or integers ranging from 1-10.

Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing. Pharmaceutical composition containing antagonists. Methods employing antagonists and agonists for modulation of quorum sensing. Compounds are exemplified by those of formula:
A-[Z].sub.n-L1-[Y].sub.q-W-[V].sub.m-L2-HG,
where A is an acyclic aliphatic group, and HG is an optionally substituted phenyl group. Compounds include those where m and n are both 0, W is —NH—, Y is present and is —CO—CH.sub.2—CO—, and L1 and L2 independently are —[CH.sub.2].sub.p1— and —[CH.sub.2].sub.p2—, where p1 and p2, independently, are 0 or integers ranging from 1-10.

An organic light-emitting device having a light-emitting layer containing a compound represented by the general formula below has a high light emission efficiency. In the general formula, at least one of R.sup.1 to R.sup.5 represents a cyano group, at least one of R.sup.1 to R.sup.5 represents a 9-carbazolyl group, a 1,2,3,4-tetrahydro-9-carbazolyl group, a 1-indolyl group or a diarylamino group, and the balance of R.sup.1 to R.sup.5 represents a hydrogen atom or a substituent.

##STR00001##

An organic light-emitting device having a light-emitting layer containing a compound represented by the general formula below has a high light emission efficiency. In the general formula, at least one of R.sup.1 to R.sup.5 represents a cyano group, at least one of R.sup.1 to R.sup.5 represents a 9-carbazolyl group, a 1,2,3,4-tetrahydro-9-carbazolyl group, a 1-indolyl group or a diarylamino group, and the balance of R.sup.1 to R.sup.5 represents a hydrogen atom or a substituent.

##STR00001##

The compounds of the present invention are represented by the following compounds having Formula I: ##STR00001##
where the substituents R.sup.1, R.sup.4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): ##STR00002##
where the substituents R.sup.1-R.sup.4, R.sup.x, R.sup.y, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

The compounds of the present invention are represented by the following compounds having Formula I: ##STR00001##
where the substituents R.sup.1, R.sup.4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): ##STR00002##
where the substituents R.sup.1-R.sup.4, R.sup.x, R.sup.y, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound. ##STR00001##